Janssen Pharmaceutical Inc.
Titusville
New Jersey
United States
615 articles about Janssen Pharmaceutical Inc.
-
New Janssen Initiative Aims to Advance Equitable Care and Address Hidden Threat of Amputation Related to Peripheral Artery Disease (PAD)
3/31/2022
The Janssen Pharmaceutical Companies of Johnson & Johnson announced the launch of Save Legs.
-
U.S. FDA Approves CABENUVA (cabotegravir and rilpivirine) for Adolescents, Expanding the Indication of the First and Only Complete Long-Acting Injectable HIV Regimen
3/30/2022
The Janssen Pharmaceutical Companies of Johnson & Johnson announced the U.S. Food and Drug Administration has approved CABENUVA for the treatment of HIV-1 in virologically suppressed adolescents who are 12 years of age or older, weigh at least 35 kg and are on a stable antiretroviral regimen, with no history of treatment failure, nor known or suspected resistance to either cabotegravir or rilpivirine.
-
Janssen Pharmaceutical's treatment for people living with human immunodeficiency virus (HIV-1) has received a label update to now include injectable administration.
-
U.S. FDA Approves Streamlined Process for Initiating HIV Therapy with CABENUVA (cabotegravir and rilpivirine), the First and Only Complete Long-Acting Injectable HIV Treatment
3/24/2022
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved a label update for CABENUVA (cabotegravir and rilpivirine).
-
Johnson & Johnson’s partner, Legend Biotech, has been awarded FDA approval for its (CAR-T) therapy, Carvykti, for the treatment of multiple myeloma disease.
-
Janssen Launches Refreshed iMaGineMyMG Campaign for People Living With Myasthenia Gravis
2/28/2022
In honor of Rare Disease Day on February 28 and the 25-30 million Americans living with rare diseases,1 the Janssen Pharmaceutical Companies of Johnson & Johnson announced the launch of the refreshed iMaGineMyMG, a national campaign aimed to increase awareness of myasthenia gravis, a chronic autoimmune neuromuscular disorder, and provide support to people living with the condition.
-
With nipocalimab, Janssen is hoping to take one big swing and knock the power right out of these autoantibodies.
-
Aqemia Announces Pilot Study with Janssen to Utilize Aqemia’s Physics-driven Drug Discovery Technology
2/14/2022
Aqemia announces it has entered into a pilot study agreement with Janssen.
-
Johnson & Johnson has temporarily paused production of its COVID-19 vaccine at its manufacturing site in The Netherlands.
-
Mersana Therapeutics Announces Research Collaboration and License Agreement with Janssen to Advance Novel Antibody-Drug Conjugates
2/3/2022
Mersana Therapeutics, Inc. announced a research collaboration and license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to discover novel ADCs for three targets.
-
Janssen Data at ASCO GU Demonstrate Longstanding Leadership in Prostate Cancer and Commitment to Advancing Potential New Therapeutic Options for Genitourinary Cancers
2/1/2022
The Janssen Pharmaceutical Companies of Johnson & Johnson announced that 17 presentations will be featured at the 2022 American Society of Clinical Oncology Genitourinary Cancers Symposium, taking place in San Francisco and virtually from February 17-19.
-
WRNMC researchers have found a way to create a vaccine that can recognize multiple spike proteins at once by using ferritin. Here's more about pan coronavirus vaccine.
-
Although most of the news about the effectiveness and endurance of COVID-19 vaccines has focused on antibody titers, not as much has been reported on their effect on other parts of the immune system that offer longer-term protection, such as T cells. For that and more, continue reading.
-
Pfizer hopes to step in to ensure that no trade secrets are disclosed when the regulatory agency begins to share that information.
-
Leyden Labs secured $140 million in a Series B financing round. Combined with $40 million from a Series A round in March 2021, the company has significant funding to advance its portfolio of candidates.
-
Gilead has announced they are pulling cancer drug Zydelig (idelalisib) off the market for certain types of cancer after failing to complete follow-up clinical trials to confirm efficacy and safety.
-
Leyden Labs Licenses Pan-Influenza Antibody from Janssen
1/18/2022
Leyden Laboratories B.V., announces the development of an intranasal spray protecting against influenza A and influenza B based on the human monoclonal antibody CR9114.
-
As 2022 gets underway, multiple companies have already announced partnerships that will advance the potential for new medications in various disease indications.
-
Korea Economic Daily, published a story saying that Samsung Group was in talks to acquire Biogen. However, Samsung BioLogics stated in a regulatory filing yesterday that the rumor is not true.
-
Janssen Submits Biologics License Application to U.S. FDA Seeking Approval of Teclistamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
12/29/2021
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of teclistamab for the treatment of patients with relapsed or refractory (R/R) multiple myeloma.